Our Pipeline

Using our proprietary drug discovery platform, we are developing a pipeline of first in class precision therapeutics that regulate key muscle proteins to address a broad array of genetically characterized muscle disorders. We have retained global development and commercialization rights to all of our programs. Our current pipeline is summarized below.
Program
Indication
Preclinical
Phase 1
Phase 2
Phase 3
EDG-5440
Next Gen Myosin ATPase Modulator
Undisclosed
Preclinical
Phase 1
Phase 2
Phase 3
EDG-002
Undisclosed Target
HFpEF, HCM
Preclinical
Phase 1
Phase 2
Phase 3
DMD - Duchenne muscular dystrophy
BMD - Becker muscular dystrophy
HCM - Hypertrophic cardiomyopathy
HFpEF - Heart failure with preserved ejection fraction
LGMD - Limb-girdle muscular dystrophy
*Phase 2 ready for DMD, LGMD and McArdle based on Phase 1 data in healthy volunteers and adults with BMD.